tirofiban

Contraindicated in:

Hypersensitivity;
Active internal bleeding or history of bleeding within previous 30 days;
History of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation or aneurysm;
History of thrombocytopenia during previous tirofiban therapy;
History of hemorrhagic stroke or other stroke within 30 days;
Major surgical procedure or severe physical trauma within 30 days;
History, symptoms, or other findings associated with aortic aneurysm;
Severe hypertension (systolic BP >180 mm Hg and/or diastolic BP >110 mm Hg);
Concurrent use of other glycoprotein IIb/IIIa receptor antagonists;
Acute pericarditis.

Use Cautiously in:

Platelet count <150,000/mm³;
Hemorrhagic retinopathy;
Females (↑ risk of bleeding);
Severe renal impairment (↓ rate of infusion if CCr ≤60 mL/min);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Safety not established in breast feeding;
Pedi: Safety and effectiveness not established in children;
Geri: ↑risk of bleeding in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

Noted for patients receiving heparin and aspirin in addition to tirofiban

CV: bradycardia, coronary dissection, edema, vasovagal reaction

Derm: hives, rash, sweating

GI: nausea

Hemat: bleeding, thrombocytopenia

MS: leg pain

Neuro: headache, dizziness

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), fever, pelvic pain

Interactions ⬆ ⬇

Drug-drug:

Concurrent use of aspirin, NSAIDs, warfarin, heparin, heparin-like agents, eptifibatide, clopidogrel, or dipyridamole may ↑ risk of bleeding, although these agents are frequently used together or in sequence.
Risk of bleeding may be ↑ by concurrent use of cefotetan valproic acid.

Drug-Natural Products:

↑anticoagulant effect and bleeding risk with anise, arnica, chamomile, clove, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, Panax ginseng, licorice, and others.

Availability ⬆ ⬇

(Generic available)

Premixed infusion: 5 mg/100 mL 0.9% NaCl; 12.5 mg/250 mL 0.9% NaCl
Solution for injection: 250 mcg/mL

Route/Dosage ⬆ ⬇

IV (Adults ): 25 mcg/kg within 5 min, then 0.15 mcg/kg/min for up to 18 hr.

Renal Impairment

IV (Adults ): CCr ≤60 mL/min—25 mcg/kg within 5 min, then 0.075 mcg/kg/min for up to 18 hr.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.

Therapeutic effects:

Inhibition of platelet aggregation resulting in decreased incidence of new MI, death, or refractory ischemia with the need for repeat cardiac procedures.

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Excreted mostly unchanged by the kidneys (65%); 25% excreted unchanged in feces.

Half-Life: 2 hr.

Time/Action Profile ⬆ ⬇

(effects on platelet function)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	30 min‡	brief‡

‡>90% inhibition of platelet aggregation at end of initial 30-min infusion.

‡Inhibition is reversible following cessation of infusion.

Patient/Family Teaching ⬆ ⬇

Explain purpose of tirofiban to patient.
Instruct patient to notify health care professional immediately if any bleeding is noted.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breast feeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

13612- Tirofiban Hydrochloride
- 13612-0009-
  - 13612-0009-0- 1 kg in 1 BAG (13612-0009-0)

13612- Tirofiban Hydrochloride
- 13612-0009-
  - 13612-0009-1- 10 kg in 1 BAG (13612-0009-1)

14537- TERUMO BCT LTD
- 14537-102-
  - 14537-102-20- 20 BAG in 1 BOX (14537-102-20) / 250 mL in 1 BAG

14789- Nexus Pharmaceuticals LLC
- 14789-101- Tirofiban Hydrochloride
  14789-101-01- 1 BAG in 1 CARTON (14789-101-01) / 100 mL in 1 BAG

14789- Nexus Pharmaceuticals LLC
- 14789-102- Tirofiban Hydrochloride
  - 14789-102-02- 1 BAG in 1 CARTON (14789-102-02) / 250 mL in 1 BAG

14789- Nexus Pharmaceuticals LLC
- 14789-102- Tirofiban Hydrochloride
  - 14789-102-10- 2 BAG in 1 CARTON (14789-102-10) / 250 mL in 1 BAG

25021- Sagent Pharmaceuticals
- 25021-417- Tirofiban Hydrochloride
  - 25021-417-84- 1 BAG in 1 CARTON (25021-417-84) / 250 mL in 1 BAG

25208- Medicure International Inc
- 25208-001- AGGRASTAT
  - 25208-001-04- 1 VIAL, GLASS in 1 CARTON (25208-001-04) / 15 mL in 1 VIAL, GLASS

25208- Medicure International Inc
- 25208-002- AGGRASTAT
  - 25208-002-01- 1 BAG in 1 CARTON (25208-002-01) / 100 mL in 1 BAG

25208- Medicure International Inc
- 25208-002- AGGRASTAT
  - 25208-002-02- 1 CONTAINER in 1 CARTON (25208-002-02) / 250 mL in 1 CONTAINER

25208- Medicure International Inc
- 25208-901- AGGRASTAT
  - 25208-901-04- 1 VIAL, GLASS in 1 CARTON (25208-901-04) / 15 mL in 1 VIAL, GLASS

25208- Medicure International Inc
- 25208-902- AGGRASTAT
  - 25208-902-01- 1 BAG in 1 CARTON (25208-902-01) / 100 mL in 1 BAG

25208- Medicure International Inc
- 25208-902- AGGRASTAT
  - 25208-902-02- 1 CONTAINER in 1 CARTON (25208-902-02) / 250 mL in 1 CONTAINER

46439- Farmabios S.p.A.
- 46439-8750-
  - 46439-8750-1- 300 g in 1 BOTTLE, GLASS (46439-8750-1)

55150- Eugia US LLC
- 55150-429- Tirofiban
  55150-429-01- 1 POUCH in 1 CARTON (55150-429-01) / 1 BAG in 1 POUCH / 100 mL in 1 BAG

55150- Eugia US LLC
- 55150-430- Tirofiban
  - 55150-430-01- 1 POUCH in 1 CARTON (55150-430-01) / 1 BAG in 1 POUCH / 250 mL in 1 BAG

68083- Gland Pharma Limited
- 68083-145- Tirofiban hydrochloride
  - 68083-145-01- 1 CONTAINER in 1 CARTON (68083-145-01) / 250 mL in 1 CONTAINER

82169- Amdipharm Limited
- 82169-025-
  - 82169-025-50- 48 VIAL, GLASS in 1 CASE (82169-025-50) / 50 mL in 1 VIAL, GLASS

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇